Skip to main content
main-content

Best of JCO™ 2018: Genitourinary Cancer Edition

Introduction

Here we provide free-to-access, full-text, original research articles published in Journal of Clinical Oncology that are some of the most-accessed in the area of genitourinary cancers.
The articles cover a range of topics including therapies for metastatic castration-resistant prostate cancer and bladder cancer. Click "Read more..." below to access full PDF versions of the articles.

Contents

1. Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer
A nationwide cohort study of data from Danish registries was conducted to examine whether statin therapy was associated with the reduced mortality in patients with prostate cancer. Read more….

2Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
This was the first head-to-head comparison of two therapies (cabazitaxel and docetaxel) that are known to prolong survival in the treatment of metastatic, castration-resistant prostate cancer. Read more....

3. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA
The PROSELICA study investigated whether cabazitaxel 20 mg/m2 was noninferior to cabazitaxel 25 mg/m2 in terms of overall survival in post-docetaxel patients with metastatic castration-resistant prostate cancer. Read more....

4. Effect of Comorbidity on Prostate Cancer–Specific Mortality: A Prospective Observational Study
This Swedish population-based study assessed the effect of comorbidities on prostate cancer-specific mortality. Read more....

​​​​​​​5. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic
This retrospective study compared clinical outcomes among patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-sparing trimodal therapy. Read more....

6. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study
This study assessed whether cardiovascular risk in patients with prostate cancer varies between those who undergo surgical castration and those who receive gonadotropin-releasing hormone agonist therapy. Read more....

7. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
This study assessed the efficacy and safety of recombinant adenovirus interferon-α with Syn3 (rAd–IFNα/Syn3) in patients with high-grade bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer. Read more....

ASCO® and the American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. The ideas and opinions expressed in the Journal of Clinical Oncology (JCO) do not necessarily reflect those of the American Society of Clinical Oncology or Springer Healthcare. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health-care provider, relying on independent experience and knowledge of the patient, to determine the appropriate treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacture for each product or therapy to be administered to verify the dosage, method, and duration of administration, or contraindications. The American Society of Clinical Oncology and Springer Healthcare assume no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication, or to any errors or omissions.

image credits